ADMA Biologics Inc (NASDAQ:ADMA) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of ADMA Biologics Inc (NASDAQ:ADMA) have been given an average rating of “Moderate Buy” by the six ratings firms that are currently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $18.6667.

A number of brokerages have recently commented on ADMA. Raymond James Financial assumed coverage on shares of ADMA Biologics in a report on Wednesday, June 10th. They issued an “outperform” rating and a $21.00 target price for the company. Wall Street Zen lowered ADMA Biologics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Canaccord Genuity Group dropped their price target on ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a research note on Thursday, June 18th. Finally, Zacks Research raised ADMA Biologics from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th.

ADMA Biologics Stock Performance

Shares of ADMA opened at $8.79 on Wednesday. The company has a current ratio of 6.95, a quick ratio of 3.93 and a debt-to-equity ratio of 0.51. The firm has a market cap of $2.04 billion, a PE ratio of 12.93 and a beta of 0.73. The company’s 50 day simple moving average is $8.48 and its 200-day simple moving average is $11.75. ADMA Biologics has a 12-month low of $7.21 and a 12-month high of $20.46.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 EPS for the quarter, meeting the consensus estimate of $0.19. The firm had revenue of $114.49 million during the quarter, compared to the consensus estimate of $139.98 million. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. ADMA Biologics’s revenue for the quarter was down .3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.11 EPS. As a group, equities analysts predict that ADMA Biologics will post 0.8 EPS for the current year.

Insider Activity

In related news, Director Jerrold B. Grossman bought 12,500 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were acquired at an average price of $8.01 per share, with a total value of $100,125.00. Following the completion of the acquisition, the director owned 513,884 shares in the company, valued at approximately $4,116,210.84. This trade represents a 2.49% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 3.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Royal Bank of Canada lifted its position in ADMA Biologics by 112.7% in the first quarter. Royal Bank of Canada now owns 95,885 shares of the biotechnology company’s stock valued at $1,903,000 after purchasing an additional 50,801 shares during the period. Ashton Thomas Private Wealth LLC acquired a new stake in shares of ADMA Biologics in the first quarter valued at approximately $217,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in ADMA Biologics by 59.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 816,590 shares of the biotechnology company’s stock valued at $16,201,000 after buying an additional 305,064 shares during the last quarter. Norges Bank purchased a new stake in ADMA Biologics during the 2nd quarter worth about $549,000. Finally, EverSource Wealth Advisors LLC grew its stake in ADMA Biologics by 385.8% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,745 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 2,180 shares during the period. 75.68% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: ADMA previously reported quarterly earnings of $0.19 per share, in line with consensus estimates, while maintaining strong liquidity ratios and profitability. A brokerage consensus price target of $18.67 also suggests substantial upside if the company’s operating performance remains intact. ADMA Biologics Receives $18.67 Consensus Price Target
• Neutral Sentiment: Multiple law firms are publicizing the same federal securities class action and an August 10, 2026 deadline for investors to seek appointment as lead plaintiff. The notices generally cover investors who purchased ADMA securities from August 9, 2024, through March 25, 2026. These announcements do not represent new regulatory findings, but they could increase uncertainty and legal expenses. ADMA Class Action Deadline Alert
• Negative Sentiment: The lawsuits allege that ADMA and certain executives misrepresented the company’s financial condition, revenue recognition, inventory distribution and business practices. Separate investor notices cite alleged channel stuffing, omitted related-party sales and false internal-control certifications, claiming ASCENIV revenue was materially overstated. The allegations have not been proven, but the potential for restatements, litigation costs, reputational damage or additional disclosures weighs on the stock. ADMA Shareholder Alert

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.